Hydrocortisone (NSC 10483)

Catalog No.S1696 Synonyms: Cortisol

For research use only.

Hydrocortisone (NSC 10483, Cortisol) is a steroid hormone or glucocorticoid produced by the adrenal gland.

Hydrocortisone (NSC 10483) Chemical Structure

CAS No. 50-23-7

Selleck's Hydrocortisone (NSC 10483) has been cited by 18 publications

Purity & Quality Control

Choose Selective Glucocorticoid Receptor Inhibitors

Biological Activity

Description Hydrocortisone (NSC 10483, Cortisol) is a steroid hormone or glucocorticoid produced by the adrenal gland.
Targets
Glucocorticoid receptor [1]
In vitro

Hydrocortisone prevents endothelial barrier breakdown in response to pro-inflammatory stimuli (TNFalpha administration) in the human brain microvascular endothelial cell line hCMEC/D3, which could be demonstrated to be partly based on maintenance of occludin levels. [1] Hydrocortisone-treated dendritic cells (DCs) show a decreased expression of MHC II molecules, the costimulatory molecule CD86, and the DC-specific marker CD83, as well as a strongly reduced IL-12 secretion. Hydrocortisone-treated DCs inhibits production of IFN-gamma but induces an increased release of IL-4 and no change in IL-5. Hydrocortisone reduces T-cell proliferation in dendritic cells. [2] Hydrocortisone prevents TNF-alpha induced severe degradation of the glycocalyx, increased coronary resistance, heightened vascular leak and permeability to hydroxyethyl starch and caused mast-cell degranulation in isolated guinea pig hearts. [3] Hydrocortisone reduces postischemic oxidative stress, perfusion pressure, and transudate formation in isolated guinea pig hearts. Hydrocortisone inhibits postischemic shedding of syndecan-1, heparan sulfate, and hyaluronan, as well as release of histamine from resident mast cells. [4] Hydrocortisone increases the levels of IL-4-induced germ line C epsilon transcripts by twofold and delivers the signal required for transcription of mature C epsilon mRNA. Hydrocortisone induces S mu-S epsilon deletional switch recombination in IL-4-treated B cells, and support a model of sequential isotype switching from IgM to IgE via IgG4. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
mouse RAW264.7 cells NUDDXXdXTnWwY4Tpc44h[XO|YYm= NXjWXmNIOjRiaB?= Ml\zRY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDpckBud3W|ZTDSRXczPjRwNzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEmITj3nZY1u[SCrbnT1Z4VlKE6RIIDyc4R2[3Srb36gZYZ1\XJiMkSgbJJ{KGK7IFfybYV{eyC{ZXHjeIlwdixiSVO1NF0xNjB4MTFOwG0> MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN4MUOzPEc,OjF|NkGzN|g9N2F-
mouse L929 cells MkfpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{fEUVYh\GG7cx?= NFW2SldIem:5dHigbY5pcWKrdHnvckBw\iCvb4Xz[UBNQTJ7IHPlcIx{KGGodHXyJFYh\GG7cx?= NFOxVY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi97Mk[xNVMoRjl{NkGxN|ww[T5?
RAW264.7 MkHMRY51cWmwZnzhcY1ifG:{eTDhd5NigQ>? M2D2emFvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgbY4hdW:3c3WgVmFYOjZ2LkegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCOUGOtbY5lfWOnZDDOU{Bxem:mdXP0bY9vKGK7IF3UWEBie3OjeTygTWM2OCB;IESwMlY1KM7:TT6= MnXZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6N{m3OFMoRjJyOEe5O|Q{RC:jPh?=
RAW264.7 MmD5SpVv[3Srb36gZZN{[Xl? NX7mVW1[OjRiaILz MVjJcohq[mm2aX;uJI9nKEySUz3pcoR2[2WmIH7peJJq[yCxeHnk[UBxem:mdXP0bY9vKGmwIH3veZNmKFKDV{K2OE44KGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDHdolme3NicnXhZ5Rqd25iYnHz[YQhe3CnY4Tyc5Bpd3SxbXX0dpktKEmFNUCgQUA1OC54NDFOwG0v NID2NXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUiwO|UyOyd-MkG4NFc2OTN:L3G+
RAW264.7 NVXWWYhOTnWwY4Tpc44h[XO|YYm= M3z0flI1KGi{cx?= MV3Jcohq[mm2aX;uJI9nKEySUz3pcoR2[2WmIF7PJJBzd2S3Y4Tpc44hcW5ibX;1d4UhWkGZMk[0Mlch[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IFfybYV{eyC{ZXHjeIlwdixiSVO1NEA:KDRyLk[0JO69VS5? MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB4N{W1NEc,OjNyNke1OVA9N2F-
RAW264.7 NWr3OoVESW62aXnu[oxidW2jdH;yfUBie3OjeR?= Mn7lNlQhcHK| M3PscWFvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgbY4hdW:3c3WgVmFYOjZ2LkegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCOUGOtbY5lfWOnZDDubZRzcWNib4jp[IUheHKxZIXjeIlwdiCjZoTldkAzPCCqcoOgZpkhT3KrZYPzJIF{e2G7LDDJR|UxKD1iNEOuPEDPxE1w MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd3NUi1NEc,OjN5NUW4OVA9N2F-
L929 NXPvW3d7TnWwY4Tpc44h[XO|YYm= M{jhblIxKGi{cx?= NYDtco5OTGm|cHzhZ4Vu\W62IH;mJFEhgCBzMDetPEBOKG:oIGuxMFItOy1|SG2teJJq[W2laX7vcI9v\SCjY3X0c45q\GViZoLvcUBodHWlb3PvdpRq[2:rZDDy[YNmeHSxcjDpckB{d2y3YnzlJIZz[WO2aX;uJI9nKG2xdYPlJGw6OjliY3XscJMh[W[2ZYKgNlAhcHK|LDDL[EA:KDBwMESzJO69VS5? MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek86OjZzMUOnQlkzPjFzM{yvZV4>
HEK293 MoDnSpVv[3Srb36gZZN{[Xl? MkHqTY5pcWKrdHnvckBw\iCPUj3t[YRq[XSnZDD0doFve2GldHn2ZZRqd25ib3[g[4Ft[WO2b4Pp[IF{\SC{ZYDvdpRmeiCpZX7lJIlvKEiHS{K5N{Bk\WyuczDlfJBz\XO|aX7nJFEy[mW2YVjTSFE> NH\NVFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNke1PVA5QCd-MU[3OVkxQDh:L3G+
RAW264.7 MUXBcpRqcW6obHHtcYF1d3K7IHHzd4F6 MniwNE42KHSxIEWwJJVoN22u NEDMUWQ1KGi{cx?= MY\BcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHHnZYlve3RiTGDTMZN1cW23bHH0[YQhdW:3c3WgVmFYOjZ2LkegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCLTD2xNEBxem:mdXP0bY9vKGG2IECuOUB1dyB3MDD1[{9udCCycnX0doVifGWmIH\vdkA1KGi{czDmc4xtd3enZDDifUBkcGGubHXu[4Uhf2m2aDCxJJVoN22OIFzQV{Bnd3JiNEigbJJ{KGK7IFXMTXNCKHKnbHH0bZZmKHSxIHPvcpRzd2x? NGTSOZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO4OFg1PSd-MkGzPFQ5PDV:L3G+
RAW264.7 NVvqdHpLSW62aXnu[oxidW2jdH;yfUBie3OjeR?= MXiwMlUhfG9iNUCgeYcwdWx? MX60JIhzew>? NHKyXWNCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIFo[Wmwc4SgUHBUNXO2aX31cIF1\WRibX;1d4UhWkGZMk[0Mlch[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDJUE03KHC{b3T1Z5Rqd25iYYSgNE42KHSxIEWwJJVoN22uIIDy[ZRz\WG2ZXSg[o9zKDRiaILzJIZwdGyxd3XkJIJ6KGOqYXzs[Y5o\SC5aYToJFEhfWdxbVygUHBUKG[xcjC0PEBpenNiYomgSWxKW0FicnXsZZRqfmVidH:gZ49vfHKxbB?= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN6NEi0OUc,OjF|OES4OFU9N2F-
RAW264.7 NXfPSXdZSW62aXnu[oxidW2jdH;yfUBie3OjeR?= MX:wMlUhfG9iNUCgeYcwdWx? NEDLSGk1KGi{cx?= MWHBcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHHnZYlve3RiTGDTMZN1cW23bHH0[YQhdW:3c3WgVmFYOjZ2LkegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCLTEGtZoV1[SCycn;keYN1cW:wIHH0JFAvPSC2bzC1NEB2\y:vbDDwdoV1emWjdHXkJIZweiB2IHjyd{Bnd2yub4fl[EBjgSClaHHscIVv\2Vid3n0bEAyKHWpL33MJGxRWyCob4KgOFghcHK|IHL5JGVNUVODIILlcIF1cX[nIITvJINwdnS{b3y= M3n1NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{i0PFQ2Lz5{MUO4OFg1PTxxYU6=
RAW264.7 NGTyWXFCdnSraX7mcIFudWG2b4L5JIF{e2G7 NVLpWWpjOC53IITvJFUxKHWpL33s NXPEemd6PCCqcoO= NUXFVGhuSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBi\2GrboP0JGxRWy2|dHnteYxifGWmIH3veZNmKFKDV{K2OE44KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gWG5H[WyyaHGgdJJw\HWldHnvckBifCByLkWgeI8hPTBidXevcYwheHKndILlZZRm\CCob4KgOEBpenNiZn;scI94\WRiYomgZ4hidGynbnflJJdqfGhiMTD1[{9uVCCOUGOg[o9zKDR6IHjyd{BjgSCHTFnTRUBz\WyjdHn2[UB1dyClb370do9t NHS1[3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO4OFg1PSd-MkGzPFQ5PDV:L3G+
RAW264.7 M2[xS2FvfGmrbn\sZY1u[XSxcomgZZN{[Xl? MkPHNE42KHSxIEWwJJVoN22u NWW1e5o1PCCqcoO= MoLIRY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDh[4FqdnO2IFzQV{1{fGmvdXzheIVlKG2xdYPlJHJCXzJ4ND63JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2Zibnn0dolkKG:6aXTlJJBzd2S3Y4Tpc44h[XRiMD61JJRwKDVyIIXnM41tKHC{ZYTy[YF1\WRiZn;yJFQhcHK|IH\vcIxwf2WmIHL5JINp[WyuZX7n[UB4cXSqIEGgeYcwdUxiTGDTJIZweiB2ODDodpMh[nliR4Lp[ZN{KHKnYXP0bY9vKG2ndHjv[EBz\WyjdHn2[UB1dyClb370do9t MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN6NEi0OUc,OjF|OES4OFU9N2F-
neural precursor cells NUKxOXhQTnWwY4Tpc44h[XO|YYm= MYDJcohq[mm2aX;uJI9nKG6ndYLvd5Bp\XKnIIDyc4xq\mW{YYTpc44hd2ZibX;1d4UhdmW3cnHsJJBz\WO3coPvdkBk\WyuczDifUBOXFRiYYPzZZk> NXLu[G9MRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0NVc3OzFpPkG3OFE4PjNzPD;hQi=>
RAW264.7 NF;a[I1CdnSraX7mcIFudWG2b4L5JIF{e2G7 NILy[IgyOCC3TR?= Mnm0NkBpenN? MVLBcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHnuJI1wfXOnIGLBW|I3PC55IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhVFCVLXnu[JVk\WRiaX7jdoVie2ViaX6gWG5HNWGucHjhJIxmfmWuIHH0JFExKHWPIHnuZ5Vj[XSnZDDmc5IhOiCqcoOgdJJqd3JidH:gUHBUKGOqYXzs[Y5o\SCvZXHzeZJm\CCjZoTldkAzOiCqcoOgZpkhTUyLU1GgdoVt[XSrdnWgeI8h[2:wdILvcC=> MlXyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MUW1OlEoRjJ3NUG1OVYyRC:jPh?=
RAW264.7 M1jFOGFvfGmrbn\sZY1u[XSxcomgZZN{[Xl? M1WyWVExKHWP MXiyJIhzew>? MVjBcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHnuJI1wfXOnIGLBW|I3PC55IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhVFCVLXnu[JVk\WRiaX7jdoVie2ViaX6gTWwuPiCuZY\lcEBifCBzMDD1UUBqdmO3YnH0[YQh\m:{IEKgbJJ{KHC{aX;yJJRwKEySUzDjbIFtdGWwZ3WgcYVie3W{ZXSgZYZ1\XJiMkKgbJJ{KGK7IFXMTXNCKHKnbHH0bZZmKHSxIHPvcpRzd2x? MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTVzNUW2NUc,OjV3MUW1OlE9N2F-
RAW264.7 MYnBcpRqcW6obHHtcYF1d3K7IHHzd4F6 MYexNEB2VQ>? MlrkNkBpenN? MY\BcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHnuJI1wfXOnIGLBW|I3PC55IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhVFCVLXnu[JVk\WRiaX7jdoVie2ViaX6gTWwuOWKndHGgcIV3\WxiYYSgNVAhfU1iaX7jeYJifGWmIH\vdkAzKGi{czDwdolweiC2bzDMVHMh[2ijbHzlcodmKG2nYYP1doVlKGGodHXyJFIzKGi{czDifUBGVEmVQTDy[YxifGm4ZTD0c{Bkd262cn;s NELhTIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWxOVU3OSd-MkW1NVU2PjF:L3G+
RAW264.7 NV\MT2poSW62aXnu[oxidW2jdH;yfUBie3OjeR?= MnrlNVAhfU1? MWWyJIhzew>? MkLLRY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDpckBud3W|ZTDSRXczPjRwNzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEySUz3pcoR2[2WmIH7peJJq[yCxeHnk[UBxem:mdXP0bY9vKGG2IEGwJJVOKGmwY4XiZZRm\CCob4KgNkBpenNicILpc5IhfG9iTGDTJINp[WyuZX7n[UBu\WG|dYLl[EBi\nSncjCyNkBpenNicnXsZZRqfmVidH:geoVpcWOuZT30doVifGWmIHPvcpRzd2x? NV31W|lKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NVU2PjFpPkK1OVE2PTZzPD;hQi=>
B16F10 M1jsUWFxd3C2b4Ppd{Bie3OjeR?= NXzRUZM5OjBidV2= NInseJc{PiCqcoO= MmDDTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDtc5V{\SCEMU\GNVAh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iY3zlZZZm\CClYYPwZZNmKDNibHX2[Ywh[XRiMkCgeW0h[W[2ZYKgN|YhcHK|IHL5JJdme3Sncn6gZoxwfCCjbnHsfZNqew>? MoLCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4OUW3N|IoRjJ4Nkm1O|MzRC:jPh?=
B16F10 NXjTNZJsSXCxcITvd4l{KGG|c3H5 NEHEXWEzOCC3TR?= MkfFN|YhcHK| NXnpcotLUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBud3W|ZTDCNVZHOTBiY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gdFU{KGW6cILld5Nqd25iYYSgNlAhfU1iYX\0[ZIhOzZiaILzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcoch[mG|ZXSgSmFEWyCjbnHsfZNqew>? NIm2fWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[5OVc{Oid-Mk[2PVU4OzJ:L3G+
B16F10 MljURZBweHSxc3nzJIF{e2G7 M{HnVFIxKHWP M2\v[lM3KGi{cx?= MUnJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIH3veZNmKEJzNl[xNEBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[YQhSmG6IHX4dJJme3Orb36gZZQhOjBidV2gZYZ1\XJiM{[gbJJ{KGK7IIfld5Rmem5iYnzveEBidmGueYPpdy=> NGnJ[2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[5OVc{Oid-Mk[2PVU4OzJ:L3G+
B16F10 MoP0RY51cXS3bX;yJIFkfGm4aYT5JIF{e2G7 MnXDOk4yOSCvZz;r[y=> M2XVNWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFKxOmYyOCClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDDOVdDVC:MIH3veZNmKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhfHWvb4Kg[5Jwf3SqIHH0JFYvOTFibXevb4ctKGmy MmHNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4OUW3N|IoRjJ4Nkm1O|MzRC:jPh?=
B16F10 M3L1U2Fxd3C2b4Ppd{Bie3OjeR?= M3[4blIxKHWP NWDNWI86OzZiaILz M2PpZmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gcY92e2ViQkG2SlExKGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHP5eI9kcHKxbXWgR{Bt\X[nbDDheEAzOCC3TTDh[pRmeiB|NjDodpMh[nlid3XzeIVzdiCkbH;0JIFv[Wy7c3nz NUTLZZdzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2PVU4OzJpPkK2Olk2PzN{PD;hQi=>
Assay
Methods Test Index PMID
Western blot parkin / AIMP2 ; CREB 28366931
Immunofluorescence Glut2 29717618
Growth inhibition assay Cell viability 22829975

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 362.46
Formula

C21H30O5

CAS No. 50-23-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC12CCC(=O)C=C1CCC3C2C(CC4(C3CCC4(C(=O)CO)O)C)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05324618 Recruiting Drug: Tacrolimus|Drug: Hydrocortisone Atopic|Dermatitis Ain Shams University|National Hepatology & Tropical Medicine Research Institute April 15 2022 Phase 4
NCT05063994 Recruiting Drug: Chronocort|Drug: Cortef Congenital Adrenal Hyperplasia Diurnal Limited December 13 2021 Phase 3
NCT05457296 Completed Drug: Hydrocortisone (capsule) Adrenal Insufficiency University Tunis El Manar January 1 2021 Phase 4

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Hydrocortisone (NSC 10483) | Hydrocortisone (NSC 10483) ic50 | Hydrocortisone (NSC 10483) price | Hydrocortisone (NSC 10483) cost | Hydrocortisone (NSC 10483) solubility dmso | Hydrocortisone (NSC 10483) purchase | Hydrocortisone (NSC 10483) manufacturer | Hydrocortisone (NSC 10483) research buy | Hydrocortisone (NSC 10483) order | Hydrocortisone (NSC 10483) mouse | Hydrocortisone (NSC 10483) chemical structure | Hydrocortisone (NSC 10483) mw | Hydrocortisone (NSC 10483) molecular weight | Hydrocortisone (NSC 10483) datasheet | Hydrocortisone (NSC 10483) supplier | Hydrocortisone (NSC 10483) in vitro | Hydrocortisone (NSC 10483) cell line | Hydrocortisone (NSC 10483) concentration | Hydrocortisone (NSC 10483) nmr